Publication

Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2-advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial

Rugo, H. S.
; 
Oliveira, M.
; 
Howell, Sacha J
; 
Dalenc, F.
; 
Cortes, J.
; 
Gomez, H. L.
; 
Hu, X. C.
; 
Iwata, H.
; 
Jhaveri, K. L.
; 
Loibl, S.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Rugo, H. S.
Oliveira, M.
Howell, Sacha J
Dalenc, F.
Cortes, J.
Gomez, H. L.
Hu, X. C.
Iwata, H.
Jhaveri, K. L.
Loibl, S.
Murillo, S. M.
Okera, M.
Park, Y. H.
Sohn, J.
Zhukova, L.
Logan, J.
Twomey, K.
Khatun, M.
D'Cruz, C. M.
Turner, N. C.
Affiliation
University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco
Description
Date
2023
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Rugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, et al. Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2-advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772000178.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/626633
Embedded videos